CCR2 and primary cutaneous T-cell non-Hodgkin lymphoma: This potential is exemplified by the ability of a small molecule inhibitor for CCR2 (CCR2i) to maximize the efficacy of PD-1 blockade in a murine model of a cutaneous T-cell lymphoma (CTCL) [126].